共 50 条
- [41] Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T TherapyBLOOD, 2020, 136Bannerji, RajatAllan, John N.Arnason, Jon E.Brown, Jennifer R.Advani, RanjanaAnsell, Stephen M.O'Brien, Susan M.Duell, JohannesMartin, PeterJoyce, Robin M.Li, JingjinFlink, Dina M.Zhu, MinWeinreich, David M.Yancopoulos, George D.Sirulnik, AndresChaudhry, AafiaAmbati, Srikanth R.Topp, Max S.
- [42] Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 StudyBLOOD, 2024, 144 : 739 - 739Montesinos, PauArnan, MontserratDe Botton, StephaneCalbacho, MariaVeiga, Rebeca RodriguezBories, PierreAnsoleaga, BelenHueso, ThomasDaver, NavalWunderle, LydiaHarstrick, AndreasPietzko, KerstinHajela, PallaviVasile, AlexandraWitte, TaniaSaenger, ElmarieRecher, Christian
- [43] Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Nooka, Ajay K.Moreau, PhilippeUsmani, Saad ZafarGarfall, Alfred L.Van De Donk, Niels W. C. J.San-Miguel, Jesus F.Oriol Rocafiguera, AlbertChari, AjaiKarlin, LionelMateos, Maria-VictoriaPopat, RakeshMartinez, JoaquinSidana, SurbhiTrancucci, DanielleVerona, RalucaGirgis, SuzetteUhlar, ClarissaStephenson, TaraBanerjee, ArnobKrishnan, Amrita Y.
- [44] A Phase 1 First-in-Human Monotherapy Study of F182112, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple MyelomaBLOOD, 2023, 142Sun, MingyuanQi, JunyuanQiu, LuguiJin, JieLi, XinWei, YongqiangZhang, GuiminLiu, XueYin, Shaohong
- [45] Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Lesokhin, Alexander M.Arnulf, BertrandNiesvizky, RubenMohty, MohamadBahlis, Nizar J.Tomasson, Michael H.Rodriguez-Otero, PaulaQuach, HangRaje, Noopur S.Iida, ShinsukeRaab, Marc-SteffenCzibere, AkosSullivan, SharonLeip, EricViqueira, AndreaLeleu, Xavier
- [46] Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Sun, MingyuanQiu, LuguiWei, YongqiangJin, JieLi, XinLiu, XueYin, ShaohongQi, Junyuan
- [47] An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Boissel, Nicolasde Botton, StephaneThomas, Xavier G.Rao, ErcoleBonnevaux, HeleneRubin-Carrez, ChantalGuerif, StephaneBeys, EricGosselin, AliceBauchet, Anne-LaureNovikov, ValeryFernandes, ElmaWiederschain, DmitriPalatinsky, Emanuel A.Hsu, KarlFraenkel, Paula Goodman
- [48] A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Daver, Naval GuastadMontesinos, PauDeAngelo, Daniel J.Wang, Eunice S.Todisco, ElisabettaTarella, CorradoMartinelli, GiovanniErba, Harry PaulDeconinck, EricSweet, Kendra L.Walter, Roland B.Levy, Moshe YairPemmaraju, NaveenLane, Andrew A.Rizzieri, DavidKonopleva, MarinaSloss, Callum MortimerWang, JiuzhouMalcolm, Kara E.Zweidler-McKay, Patrick A.
- [49] A phase 1, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (claudin-6 x CD3) T-cell engaging bispecific antibody in subjects with germ cell tumors and other advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS652 - TPS652Levitz, DavidGutierrez, MartinWiner, Ira SethReilley, MatthewDuska, Linda R.Subbiah, VivekRichardson, Debra L.Bohac, ChetChiarella, MichaelNaranjo, CarlosKanodia, JitendraWoo, JackyNevadunsky, Nicole
- [50] A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumorsONCOIMMUNOLOGY, 2018, 7 (08):Kebenko, MaximGoebeler, Marie-ElisabethWolf, MartinHasenburg, AnnetteSeggewiss-Bernhardt, RuthRitter, BarbaraRautenberg, BeateAtanackovic, DjordjeKratzer, AndreaRottman, James B.Friedrich, MatthiasVieser, EvaElm, StefaniePatzak, IngridWessiepe, DorotheaStienen, SabineFiedler, Walter